{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:06:54Z","timestamp":1794661614818,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1208\/s12248-017-0155-8","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T16:35:17Z","timestamp":1511800517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram"],"prefix":"10.1208","volume":"20","author":[{"given":"Nikunjkumar","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wi\u015bniowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Jamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"155_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/DHPS.S91046","volume":"7","author":"KJ Friesen","year":"2015","unstructured":"Friesen KJ, Bugden SC. The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram. Drug Healthc Patient Saf. 2015;7:139\u201345. https:\/\/doi.org\/10.2147\/DHPS.S91046 .","journal-title":"Drug Healthc Patient Saf"},{"key":"155_CR2","unstructured":"US Food and Drug Adminstration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Silver Spring, MD: US Food and Drug Adminstration; 2011. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm269086.htm ."},{"key":"155_CR3","unstructured":"US Food and Drug Adminstration. FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Silver Spring, MD: US Food and Drug Adminstration; 2012. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm297391.htm ."},{"key":"155_CR4","unstructured":"Over\u00f8 K, Hojelse F. The unexpected preclinical finding-elucidation of dog toxicity-citalopram. In Excerpts from a workshop on the use of pharmacology studies in drug safety assessment - present situation and future perspectives: September 26\u201327, Stockholm, Sweden. Stockholm: Association of the Swedish Pharmeceutical Industry (Lakemedelsindustriforen.) (LIF); Uppsala: Medical Products Agency [Lakemedelsverket]; 1994. p. 113\u20136."},{"issue":"2","key":"155_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.vascn.2012.08.040","volume":"66","author":"J Rohrbacher","year":"2012","unstructured":"Rohrbacher J, Bex P, Gallacher DJ. Citalopram metabolites inhibit IKs and IKr differentially: is this a possible explanation for the sudden deaths in dogs? J Pharmacol Toxicol Meth. 2012;66(2):170. https:\/\/doi.org\/10.1016\/j.vascn.2012.08.040 .","journal-title":"J Pharmacol Toxicol Meth"},{"issue":"1-3","key":"155_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0014-5793(01)03320-8","volume":"512","author":"HJ Witchel","year":"2002","unstructured":"Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 2002;512(1-3):59\u201366. https:\/\/doi.org\/10.1016\/S0014-5793(01)03320-8 .","journal-title":"FEBS Lett"},{"issue":"3","key":"155_CR7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.33549\/physiolres.930216","volume":"51","author":"J Hamplova-Peichlova","year":"2002","unstructured":"Hamplova-Peichlova J, Krusek J, Paclt I, Slavicek J, Lisa V, Vyskocil F. Citalopram inhibits L-type calcium channel current in rat cardiomyocytes in culture. Physiol Res. 2002;51(3):317\u201321.","journal-title":"Physiol Res"},{"issue":"6","key":"155_CR8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2174\/0929867306666220330184544","volume":"6","author":"P Pacher","year":"1999","unstructured":"Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6(6):469\u201380.","journal-title":"Curr Med Chem"},{"issue":"2","key":"155_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2125.2005.02546.x","volume":"61","author":"LE Friberg","year":"2006","unstructured":"Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol. 2006;61(2):177\u201390. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02546.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"155_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1176\/appi.ajp.2013.13070905","volume":"171","author":"ST Bird","year":"2014","unstructured":"Bird ST, Crentsil V, Temple R, Pinheiro S, Demczar D, Stone M. Cardiac safety concerns remain for citalopram at dosages above 40 mg\/day. Am J Psychiatry. 2014;171(1):17\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13070905 .","journal-title":"Am J Psychiatry"},{"issue":"6","key":"155_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1176\/appi.ajp.2013.12030408","volume":"170","author":"K Zivin","year":"2013","unstructured":"Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013;170(6):642\u201350. https:\/\/doi.org\/10.1176\/appi.ajp.2013.12030408 .","journal-title":"Am J Psychiatry"},{"issue":"3","key":"155_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0897190015624862","volume":"30","author":"LM Hutton","year":"2016","unstructured":"Hutton LM, Cave AJ, St-Jean R, Banh HL. Should we be worried about QTc prolongation using citalopram? A review. J Pharm Pract. 2016;30(3):353\u20138. https:\/\/doi.org\/10.1177\/0897190015624862 .","journal-title":"J Pharm Pract"},{"issue":"3","key":"155_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.drudis.2013.10.009","volume":"19","author":"S Polak","year":"2014","unstructured":"Polak S, Wisniowska B, Fijorek K, Glinka A, Mendyk A. In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discov Today. 2014;19(3):275\u201381. https:\/\/doi.org\/10.1016\/j.drudis.2013.10.009 .","journal-title":"Drug Discov Today"},{"issue":"11","key":"155_CR14","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1016\/j.xphs.2016.08.002","volume":"105","author":"B Wisniowska","year":"2016","unstructured":"Wisniowska B, Polak S. Virtual clinical trial toward polytherapy safety assessment: combination of physiologically based pharmacokinetic\/pharmacodynamic-based modeling and simulation approach with drug-drug interactions involving terfenadine as an example. J Pharm Sci. 2016;105(11):3415\u201324. https:\/\/doi.org\/10.1016\/j.xphs.2016.08.002 .","journal-title":"J Pharm Sci"},{"issue":"2","key":"155_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/15376516.2016.1256460","volume":"27","author":"M Abbasi","year":"2017","unstructured":"Abbasi M, Small BG, Patel N, Jamei M, Polak S. Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept. Toxicol Mech Methods. 2017;27(2):88\u201399. https:\/\/doi.org\/10.1080\/15376516.2016.1256460 .","journal-title":"Toxicol Mech Methods"},{"issue":"1","key":"155_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.drudis.2016.09.027","volume":"22","author":"B Wisniowska","year":"2017","unstructured":"Wisniowska B, Polak S. Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity. Drug Discov Today. 2017;22(1):10\u20136. https:\/\/doi.org\/10.1016\/j.drudis.2016.09.027 .","journal-title":"Drug Discov Today"},{"key":"155_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","volume":"81","author":"T Colatsky","year":"2016","unstructured":"Colatsky T, Fermini B, Gintant G, Pierson JB, Sager P, Sekino Y, et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative\u2014update on progress. J Pharmacol Toxicol Methods. 2016;81:15\u201320. https:\/\/doi.org\/10.1016\/j.vascn.2016.06.002 .","journal-title":"J Pharmacol Toxicol Methods"},{"key":"155_CR18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","volume":"81","author":"WJ Crumb Jr","year":"2016","unstructured":"Crumb WJ Jr, Vicente J, Johannesen L, Strauss DG. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J Pharmacol Toxicol Methods. 2016;81:251\u201362.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"155_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.vascn.2016.05.012","volume":"81","author":"I Cavero","year":"2016","unstructured":"Cavero I, Guillon JM, Ballet V, Clements M, Gerbeau JF, Holzgrefe H. Comprehensive in vitro Proarrhythmia Assay (CiPA): pending issues for successful validation and implementation. J Pharmacol Toxicol Methods. 2016;81:21\u201336. https:\/\/doi.org\/10.1016\/j.vascn.2016.05.012 .","journal-title":"J Pharmacol Toxicol Methods"},{"key":"155_CR20","first-page":"12","volume":"17","author":"B Wisniowska","year":"2016","unstructured":"Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect\u2014comprehensive overview of clinical trials. BMC. Pharmacol Toxicol. 2016;17:12.","journal-title":"Pharmacol Toxicol"},{"key":"155_CR21","unstructured":"Tucker GT, Rostami-Hodjegan A, Toon S, inventors; Systems and methods for predicting and adjusting the dosage of medicines in individual patients. US Patent 2016\/0335412 A1 Filed Jan 27, 2014."},{"issue":"4","key":"155_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.paid.2011.11.019","volume":"53","author":"NL Segal","year":"2012","unstructured":"Segal NL, McGuire SA, Stohs JH. What virtual twins reveal about general intelligence and other behaviors. Pers Individ Dif. 2012;53(4):405\u201310. https:\/\/doi.org\/10.1016\/j.paid.2011.11.019 .","journal-title":"Pers Individ Dif"},{"key":"155_CR23","unstructured":"Bedding A, Scott G, Brayshaw N, Leong L, Herrero-Martinez E, Looby M, et al. Clinical trial simulations\u2014an essential tool in drug development. The Association of the British Pharmaceutical Industry; 2014. http:\/\/www.abpi.org.uk\/our-work\/library\/industry\/Documents\/trial_design.pdf ."},{"issue":"5","key":"155_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10928-016-9492-y","volume":"43","author":"C Hartmanshenn","year":"2016","unstructured":"Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn. 2016;43(5):481\u2013504. https:\/\/doi.org\/10.1007\/s10928-016-9492-y .","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"155_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","volume":"2","author":"M Jamei","year":"2016","unstructured":"Jamei M. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Curr Pharmacol Rep. 2016;2(3):161\u20139. https:\/\/doi.org\/10.1007\/s40495-016-0059-9 .","journal-title":"Curr Pharmacol Rep"},{"issue":"8","key":"155_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s11095-016-2076-0","volume":"34","author":"GT Tucker","year":"2017","unstructured":"Tucker GT. Personalized drug dosage\u2014closing the loop. Pharm Res. 2017;34(8):1539\u201343. https:\/\/doi.org\/10.1007\/s11095-016-2076-0 .","journal-title":"Pharm Res"},{"issue":"3","key":"155_CR27","doi-asserted-by":"publisher","first-page":"H1088","DOI":"10.1152\/ajpheart.00109.2006","volume":"291","author":"KH Tusscher ten","year":"2006","unstructured":"ten Tusscher KH, Panfilov AV. Alternans and spiral breakup in a human ventricular tissue model. Am J Physiol Heart Circ Physiol. 2006;291(3):H1088\u2013100. https:\/\/doi.org\/10.1152\/ajpheart.00109.2006 .","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"155_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12265-012-9357-8","volume":"5","author":"S Polak","year":"2012","unstructured":"Polak S, Fijorek K. Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment\u2014analysis of the age-cardiomyocytes electric capacitance dependence. J Cardiovasc Transl Res. 2012;5(3):321\u201332. https:\/\/doi.org\/10.1007\/s12265-012-9357-8 .","journal-title":"J Cardiovasc Transl Res"},{"issue":"1","key":"155_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/15376516.2011.585477","volume":"22","author":"S Polak","year":"2012","unstructured":"Polak S, Fijorek K, Glinka A, Wisniowska B, Mendyk A. Virtual population generator for human cardiomyocytes parameters: in silico drug cardiotoxicity assessment. Toxicol Mech Methods. 2012;22(1):31\u201340. https:\/\/doi.org\/10.3109\/15376516.2011.585477 .","journal-title":"Toxicol Mech Methods"},{"issue":"4","key":"155_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3109\/01480545.2011.566571","volume":"34","author":"J Liotier","year":"2011","unstructured":"Liotier J, Coudor\u00e9 F. Drug monitoring of a case of citalopram overdosage. Drug Chem Toxicol. 2011;34(4):420\u20133. https:\/\/doi.org\/10.3109\/01480545.2011.566571 .","journal-title":"Drug Chem Toxicol"},{"issue":"2","key":"155_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF03160963","volume":"4","author":"AF Tarabar","year":"2008","unstructured":"Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol. 2008;4(2):101\u20135. https:\/\/doi.org\/10.1007\/BF03160963 .","journal-title":"J Med Toxicol"},{"issue":"1","key":"155_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/s-0031-1286346","volume":"45","author":"S Unterecker","year":"2012","unstructured":"Unterecker S, Warrings B, Deckert J, Pfuhlmann B. Correlation of QTc interval prolongation and serum level of citalopram after intoxication\u2014a case report. Pharmacopsychiatry. 2012;45(1):30\u20134. https:\/\/doi.org\/10.1055\/s-0031-1286346 .","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"155_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bcp.12348","volume":"78","author":"Y Ji","year":"2014","unstructured":"Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014;78(2):373\u201383. https:\/\/doi.org\/10.1111\/bcp.12348 .","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"155_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2193-9616-1-9","volume":"1","author":"M Jamei","year":"2013","unstructured":"Jamei M, Marciniak S, Edwards D, Wragg K, Feng K, Barnett A, et al. The Simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol. 2013;1(1):9. https:\/\/doi.org\/10.1186\/2193-9616-1-9 .","journal-title":"In Silico Pharmacol"},{"issue":"2","key":"155_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/17425250802691074","volume":"5","author":"M Jamei","year":"2009","unstructured":"Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5(2):211\u201323. https:\/\/doi.org\/10.1517\/17425250802691074 .","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"155_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1023\/B:MODI.0000006562.93049.36","volume":"7","author":"M Lobell","year":"2003","unstructured":"Lobell M, Sivarajah V. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Divers. 2003;7(1):69\u201387. https:\/\/doi.org\/10.1023\/B:MODI.0000006562.93049.36 .","journal-title":"Mol Divers"},{"key":"155_CR37","first-page":"287","volume":"6","author":"P Baumann","year":"1995","unstructured":"Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmaco. 1995;6:287\u201395.","journal-title":"Rev Contemp Pharmaco"},{"issue":"6","key":"155_CR38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40495-016-0075-9","volume":"2","author":"B Wisniowska","year":"2016","unstructured":"Wisniowska B, Polak S. The role of interaction model in simulation of drug interactions and QT prolongation. Curr. Pharmacol Rep. 2016;2(6):339\u201344. https:\/\/doi.org\/10.1007\/s40495-016-0075-9 .","journal-title":"Pharmacol Rep"},{"issue":"1","key":"155_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1742-4682-10-7","volume":"10","author":"K Fijorek","year":"2013","unstructured":"Fijorek K, Patel N, Klima L, Stolarz-Skrzypek K, Kawecka-Jaszcz K, Polak S. Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study. Theor Biol Med Model. 2013;10(1):7. https:\/\/doi.org\/10.1186\/1742-4682-10-7 .","journal-title":"Theor Biol Med Model"},{"key":"155_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/429037","volume":"2013","author":"K Fijorek","year":"2013","unstructured":"Fijorek K, Puskulluoglu M, Polak S. Circadian models of serum potassium, sodium, and calcium concentrations in healthy individuals and their application to cardiac electrophysiology simulations at individual level. Comput Math Methods Med. 2013;2013:429037. https:\/\/doi.org\/10.1155\/2013\/429037 .","journal-title":"Comput Math Methods Med"},{"issue":"2","key":"155_CR41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1542-474X.1997.tb00325.x","volume":"2","author":"HC Bazett","year":"1997","unstructured":"Bazett HC. An analysis of the time-relations of electrocardiograms. Ann Noninvasive Electrocardiol. 1997;2(2):177\u201394. https:\/\/doi.org\/10.1111\/j.1542-474X.1997.tb00325.x .","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"6","key":"155_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1023\/A:1014460404352","volume":"28","author":"T Minematsu","year":"2001","unstructured":"Minematsu T, Ohtani H, Yamada Y, Sawada Y, Sato H, Iga T. Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic\/pharmacodynamic model incorporating a site of adverse effect. J Pharmacokinet Pharmacodyn. 2001;28(6):533\u201354. https:\/\/doi.org\/10.1023\/A:1014460404352 .","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"155_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/bdd.1944","volume":"36","author":"Z Tylutki","year":"2015","unstructured":"Tylutki Z, Polak S. Plasma vs heart tissue concentration in humans\u2014literature data analysis of drugs distribution. Biopharm Drug Dispos. 2015;36(6):337\u201351. https:\/\/doi.org\/10.1002\/bdd.1944 .","journal-title":"Biopharm Drug Dispos"},{"key":"155_CR44","doi-asserted-by":"publisher","first-page":"39494","DOI":"10.1038\/srep39494","volume":"7","author":"Z Tylutki","year":"2017","unstructured":"Tylutki Z, Polak S. A four-compartment PBPK heart model accounting for cardiac metabolism\u2014model development and application. Sci Rep. 2017;7:39494. https:\/\/doi.org\/10.1038\/srep39494 .","journal-title":"Sci Rep"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-017-0155-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-017-0155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-017-0155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T02:57:58Z","timestamp":1719629878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-017-0155-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["155"],"URL":"https:\/\/doi.org\/10.1208\/s12248-017-0155-8","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]},"article-number":"6"}}